

AN OVERVIEW OF FRONTOTEMPORAL DEMENTIA



Kimiko Domoto-Reilly, MD
University of Washington
Memory & Brain Wellness Center
Alzheimer's Disease Research Center
Integrated Brain Imaging Center
August 13th 2021

FTD: Demographics

- 3rd most common neurodegenerative dementia
 - 15% of all dementias
 - most common early onset dementia (50s-60s)
 - rare (fewer than 200,000 people with FTD in the US)
 - 7-10 year course
 - 20-30% familial



FTLD spectrum disorders

- behavioral variant (bvFTD)
- language variants (primary progressive aphasia / PPA)
 - semantic variant
 - nonfluent/agrammatic variant
- progressive supranuclear palsy (PSP)
- corticobasal syndrome (CBS / CBD)

bvFTD/PPA Diagnostic Criteria

- slowly progressive decline in behavior / cognition
 - social / executive / language dysfunction
 - most prominent feature, root cause of daily impairment
- not better accounted for by another medical / neurologic / psychiatric disorder
- clinical diagnosis (“possible”)
 - supportive functional / structural imaging → “probable”
 - genetic mutation / expansion
 - FTLD histopathology
 - usually TDP₄₃ or tau

Diagnostic Criteria: bvFTD (possible)

- Presence of persistent, recurrent symptoms (3)
 - disinhibition
 - social inappropriateness; loss of manners; impulsivity
 - apathy / inertia
 - loss of sympathy / empathy
 - diminished response to others; diminished social engagement
 - perseveration or compulsion
 - repetitive movements; complex rituals; speech stereotypy
 - hyperorality or dietary changes
 - Δ food preference; binge eat, tob, EtOH; oral exploration
 - neuropsychological profile
 - exec dysfunction with sparing of episodic mem and visuospat

Diagnostic Criteria: bvFTD (probable)

- meets criteria for possible bvFTD
- *progressive* behavioral decline
- functionally impaired due to cognitive / behavioral / social issues


and

- supporting structural or functional imaging findings
 - frontal and/or anterior temporal atrophy
 - frontal and/or anterior temporal hypoperfusion/hypometabolism



exclusionary

- biomarker evidence of Alzheimer's disease

Imaging: bvFTD



Functional brain imaging: FTD vs AD



Diagnostic Criteria: PPA

- Core criteria:
 - most prominent feature is difficulty with language
 - language impairment is the principal cause of impaired daily living activities
 - aphasia is the most prominent deficit at symptom onset and for initial disease phases

- Exclusionary criteria:
 - another non-degenerative neurologic, psychiatric, or medical process better accounts for the clinical symptoms
 - prominent initial episodic memory, visual memory, or visuosperceptual impairment
 - prominent initial behavioral disturbance

Diagnostic Criteria: svPPA

- Core criteria (2):
 - impaired confrontation naming
 - impaired single word comprehension

- Supporting features (3):
 - impaired object knowledge (esp low freq)
 - surface dyslexia / dysgraphia
 - spared repetition
 - spared grammar and motor speech production

Diagnostic Criteria: nfvPPA

- Core criteria (1):
 - agrammatism
 - speech apraxia

- Supporting features (2):
 - impaired comprehension of syntactically complex sentences
 - spared single-word comprehension
 - spared object knowledge



Diagnostic Criteria: PPA (probable)

- clinical diagnosis of a PPA variant
 - initial prominent, isolated, progressive language impairment
 - ADLs only affected by language issues





and

- supporting structural/functional imaging findings
 - svPPA: anterior temporal lobe
 - typically TDP₄₃ neuropathology
 - nfvPPA: L posterior fronto-insular cortex
 - typically tau neuropathology



Imaging: svPPA



Imaging: svPPA




Imaging: nfvPPA



Progression Over Time

- cognitive changes
 - behavior ↔ language; memory
- motor changes
 - Parkinsonism, restriction of eye movements, motor neuron disease (MND)
- survival is 2-20+ years after diagnosis
 - average is 7-8 years
 - depends in part on how early the diagnosis is made
 - shortest: FTD-MND / longest: svPPA



Variable Time Course of Symptoms



FTD Genetics

- 3 major genes
 - *C9orf72*
 - *GRN*
 - *MAPT*
- autosomal dominant; nearly 100% penetrant
 - variable age of onset and symptomatology
- the majority of FTD (70-80%) is not due to a single gene variant
- identifying a FTD gene variant also identifies the neuropathology subtype (e.g., tau or TDP-43)

*clinical
presentation*



neuropathology



genetics



Treatment

- disease modifying medication (slow / stop / reverse)
 - none currently, except for MND
- symptomatic medications
 - nothing is yet proven
 - typically avoid Alzheimer's medications
 - antidepressants / mood stabilizers: SSRIs, valproate
 - antipsychotics
 - stimulants?
- non-pharmacologic treatment
 - SLP (cog rehab, LSVT, AAC, swallow eval), PT, OT

Compensatory strategies: Behavioral

- household responsibilities
 - break down tasks into manageable steps
 - activity templates
 - daily schedule for activities, chores
- set up routines with a companion
 - non-family member can initiate activities
 - structured environment can be beneficial
- roaming
 - medical alert bracelet, pocket cards

Compensatory strategies: Communication

- slow down
 - more time to think of words, organize thoughts
 - more time to process what is being said
- eliminate distractors
 - one-on-one conversation typically better
- provide multimodal prompts
 - partner asks multiple choice or yes/no questions
 - use gestures, facial expression, visual aids (pic/word)

Online & Local Resources

- Association for Frontotemporal Degeneration
 - www.theAFTD.org
- Rare Dementia Support
 - www.raredementiasupport.org
- FTD Talk
 - www.ftdtalk.org
- CurePSP
 - www.psp.org
- UW Speech & Hearing Sciences Clinic
 - sphsc.washington.org/clinic